NCT05142592: IPG7236 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Triple negative breast cancer (TNBC) patients are also eligible for the Part 2 dose expansion phase
Exclusions: Patients with symptomatic or untreated leptomeningeal or brain metastases – see trial for details

Comments are closed.

Up ↑